Patterns and associations between DAPT cessation and 2-year clinical outcomes in left main/proximal LAD versus other PCI: Results from the Patterns of Non-Adherence to Dual Antiplatelet Therapy in Stented Patients (PARIS) registry.

[1]  J. Hartikainen,et al.  Percutaneous coronary angioplasty versus coronary artery bypass grafting in treatment of unprotected left main stenosis (NOBLE): a prospective, randomised, open-label, non-inferiority trial , 2016, The Lancet.

[2]  S. Pocock,et al.  Everolimus-Eluting Stents or Bypass Surgery for Left Main Coronary Artery Disease. , 2016, The New England journal of medicine.

[3]  S. Pocock,et al.  Coronary Thrombosis and Major Bleeding After PCI With Drug-Eluting Stents: Risk Scores From PARIS. , 2016, Journal of the American College of Cardiology.

[4]  J. Spertus,et al.  Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention. , 2016, JAMA.

[5]  E. Mahmud,et al.  Predictors and outcomes of recurrent stent thrombosis: results from a multicenter registry. , 2014, JACC. Cardiovascular interventions.

[6]  M. Mack,et al.  Five-Year Outcomes in Patients With Left Main Disease Treated With Either Percutaneous Coronary Intervention or Coronary Artery Bypass Grafting in the Synergy Between Percutaneous Coronary Intervention With Taxus and Cardiac Surgery Trial , 2014, Circulation.

[7]  A. Kastrati,et al.  Zotarolimus- versus everolimus-eluting stents for unprotected left main coronary artery disease. , 2013, Journal of the American College of Cardiology.

[8]  Antonio Colombo,et al.  Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study , 2013, The Lancet.

[9]  A. Colombo,et al.  Two-year outcomes following unprotected left main stenting with first vs. new-generation drug-eluting stents: the FINE registry. , 2013, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[10]  M. Morice,et al.  Two-year outcomes of everolimus vs. paclitaxel-eluting stent for the treatment of unprotected left main lesions: a propensity score matching comparison of patients included in the French Left Main Taxus (FLM Taxus) and the LEft MAin Xience (LEMAX) registries. , 2013, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[11]  Akshay S. Desai,et al.  Strategies for multivessel revascularization in patients with diabetes. , 2012, The New England journal of medicine.

[12]  H. White,et al.  Development and validation of a stent thrombosis risk score in patients with acute coronary syndromes. , 2012, JACC. Cardiovascular interventions.

[13]  P. Teirstein,et al.  Left main percutaneous coronary intervention. , 2012, Journal of the American College of Cardiology.

[14]  Samin K. Sharma,et al.  Safety of temporary and permanent suspension of antiplatelet therapy after drug eluting stent implantation in contemporary "real-world" practice. , 2012, Journal of interventional cardiology.

[15]  E. Mahmud,et al.  Angiographic stent thrombosis at coronary bifurcations: short- and long-term prognosis. , 2012, JACC. Cardiovascular interventions.

[16]  Helmut Baumgartner,et al.  ESC / EACTS Guidelines on myocardial revascularization , 2014 .

[17]  J. Fajadet,et al.  Current management of left main coronary artery disease. , 2012, European heart journal.

[18]  Laura Mauri,et al.  2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. , 2011, Circulation.

[19]  G. Levine,et al.  2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. , 2011, Journal of the American College of Cardiology.

[20]  Marco Valgimigli,et al.  Standardized Bleeding Definitions for Cardiovascular Clinical Trials: A Consensus Report From the Bleeding Academic Research Consortium , 2011, Circulation.

[21]  I. Iakovou,et al.  Is there a higher risk of stent thrombosis in bifurcation lesion or is it related to the technique? , 2010, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[22]  Gary S. Mintz,et al.  Intravascular Ultrasound Classification of Plaque Distribution in Left Main Coronary Artery Bifurcations: Where Is the Plaque Really Located? , 2010, Circulation. Cardiovascular interventions.

[23]  Seung‐Jung Park,et al.  Percutaneous Coronary Intervention With Stent Implantation Versus Coronary Artery Bypass Surgery for Treatment of Left Main Coronary Artery Disease: Is It Time to Change Guidelines? , 2009, Circulation. Cardiovascular interventions.

[24]  C. McHorney,et al.  The Adherence Estimator: a brief, proximal screener for patient propensity to adhere to prescription medications for chronic disease. , 2009, Current medical research and opinion.

[25]  Jeroen J. Bax,et al.  Universal definition of myocardial infarction. , 2007 .

[26]  P. Serruys,et al.  Clinical End Points in Coronary Stent Trials: A Case for Standardized Definitions , 2007, Circulation.

[27]  Timothy J Gardner,et al.  Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American D , 2007, Circulation.

[28]  C. Grines,et al.  Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American D , 2007, Journal of the American College of Cardiology.

[29]  C. Grines,et al.  Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American D , 2007, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[30]  B. Gersh,et al.  Prevalence, Predictors, and Outcomes of Premature Discontinuation of Thienopyridine Therapy After Drug-Eluting Stent Placement: Results From the PREMIER Registry , 2007 .

[31]  Harlan M. Krumholz,et al.  Prevalence, Predictors, and Outcomes of Premature Discontinuation of Thienopyridine Therapy After Drug-Eluting Stent Placement: Results From the PREMIER Registry , 2006, Circulation.

[32]  P. Serruys,et al.  Distal left main coronary disease is a major predictor of outcome in patients undergoing percutaneous intervention in the drug-eluting stent era: an integrated clinical and angiographic analysis based on the Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) and Taxus-Sten , 2006, Journal of the American College of Cardiology.

[33]  Seung‐Jung Park,et al.  Sirolimus-eluting stent implantation for unprotected left main coronary artery stenosis: comparison with bare metal stent implantation. , 2005, Journal of the American College of Cardiology.

[34]  S. Lemeshow,et al.  European system for cardiac operative risk evaluation (EuroSCORE). , 1999, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[35]  S. Nashef,et al.  Eurp-pean system for cardiac operative risk evaluation (Euro SCORE) , 1999 .

[36]  R. Califf,et al.  27th Bethesda Conference: matching the intensity of risk factor management with the hazard for coronary disease events. Task Force 5. Stratification of patients into high, medium and low risk subgroups for purposes of risk factor management. , 1996, Journal of the American College of Cardiology.